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Results from the majority of studies show little association between circulating concentrations of vitamin D and
prostate cancer risk, a ﬁnding that has not been demonstrated in a wider European population, however. The
authors examined whether vitamin D concentrations were associated with prostate cancer risk in a case-control
study nested within the European Prospective Investigation into Cancer and Nutrition (1994–2000). Serum con-
centrations of 25-hydroxyvitamin D were measured in 652 prostate cancer cases matched to 752 controls from 7
European countries after a median follow-up time of 4.1 years. Conditional logistic regression models were used to
calculate odds ratios for prostate cancer risk in relation to serum 25-hydroxyvitamin D after standardizing for month
of blood collection and adjusting for covariates. No signiﬁcant association was found between 25-hydroxyvitamin D
and risk of prostate cancer (highest vs. lowest quintile: odds ratio ¼ 1.28, 95% conﬁdence interval: 0.88, 1.88; P for
trend ¼ 0.188). Subgroup analyses showed no signiﬁcant heterogeneity by cancer stage or grade, age at di-
agnosis, body mass index, time from blood collection to diagnosis, or calcium intake. In summary, the results of
this large nested case-control study provide no evidence in support of a protective effect of circulating concen-
trations of vitamin D on the risk of prostate cancer.
prostatic neoplasms; serum; vitamin D; 25-hydroxyvitamin D 2
Abbreviations: EPIC, European Prospective Investigation into Cancer and Nutrition; 1,25(OH)2D, 1,25-dihydroxyvitamin D;
25(OH)D, 25-hydroxyvitamin D.
In 1990, ﬁndings of an inverse association between
ultraviolet exposure and prostate cancer mortality rates
in the United States led to the hypothesis that vitamin
D insufﬁciency may increase prostate cancer risk (1).
Results from experimental studies in animal models and
cell lines as well as a phase II clinical trial support the
hypothesis that vitamin D may play a role in the etiology
of prostate cancer (2–4); however, evidence from pro-
spective studies in the United States and Nordic countries
that have assessed the relation between circulating con-
centrations of 25-hydroxyvitamin D (25(OH)D) and 1,25-
dihydroxyvitamin D (1,25(OH)2D) and risk of prostate
cancer has not clearly supported such an association
(5–16). Despite the consistent ﬁnding of no association
between circulating concentrations of vitamin D and the
risk of prostate cancer, there is still considerable support
for vitamin D insufﬁciency as a risk factor for prostate
cancer (17, 18). To date, we know of no study that has
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ropean countries.
We examine here the relation between prediagnostic se-
rum concentrations of 25(OH)D and risk of prostate cancer
among 652 men with incident prostate cancer and 752
matched controls participating in a large, multicenter cohort
study: the European Prospective Investigation into Cancer
and Nutrition (EPIC). We also evaluate these associations
by stage and grade of disease.
MATERIALS AND METHODS
Participants
The methods of recruitment for EPIC and the design of the
studyhavebeendescribedindetailelsewhere(19).Thepresent
study includes prostate cancer cases diagnosed after blood
collection and individually matched to controls from 7 of the
10participatingcountries:Germany,Greece,Italy,theNether-
lands, Spain, Sweden, and the United Kingdom. France and
Norway, and the regional centers in Utrecht, the Netherlands,
and Naples, Italy, were not included in the current study be-
causethesecohortsincludedwomenonly.CentersinDenmark
and Malmo ¨, Sweden, did not contribute data to the current
study. Each case was matched to 1 control, except in Umea ˚,
Sweden,whereeachcasewasmatchedto2controls.Matching
criteriawerestudycenter,ageatenrollment(66months),time
of day of blood collection (61 hour), and time between blood
drawandlastconsumptionoffoodordrink(<3,3–6,>6hours;
for Umea ˚ <4, 4–8, >8 hours). A more detailed description of
follow-up for cancer incidence and the selection of cases and
controls has been published elsewhere (20).
Diet and lifestyle questionnaires
Dietary intake during the year before recruitment was
measured by country-speciﬁc validated dietary question-
naires designed to capture local dietary patterns. Informa-
tion on validation of the food questionnaires has been
published previously (19, 21). Calcium intakes were calcu-
lated by multiplying the calcium content of each food of
a speciﬁc portion size or quantity (in grams) by the fre-
quency of consumption as stated on the food questionnaire
using country-speciﬁc national food tables. Intake from sup-
plemental calcium was not included in this analysis.
Blood collection
A 30-mL blood sample was collected from 139,207
(91%) of the 153,457 men participating in EPIC according
to a standardized protocol at the time of recruitment. Filled
syringes were kept at 5 C–10 C, protected from light, and
transferred to a local laboratory for further processing and
aliquoting, except for participants recruited through the Ox-
ford center. Here, blood samples were collected throughout
the United Kingdom and were transported to a laboratory in
Norfolk by mail at ambient temperature. Blood for serum
was aliquoted into 0.5-mL straws, which were then heat-
sealed at both ends and stored in liquid nitrogen tanks
at  196 C, except for Umea ˚, where samples were stored
in 1.5-mL plastic tubes at  70 C.
Laboratory assays
Serum 25(OH)D concentration was determined by en-
zyme immunoassay (OCTEIA 25-Hydroxy Vitamin D kit;
Immunodiagnostic Systems, Limited, Bolton, Tyne and
Wear, United Kingdom) in the Medical Research Council
Human Nutrition Research laboratories in Cambridge by
laboratory personnel blinded to the case or control status
of participants. Serum samples from each case-control set
were assayed within the same batch. The intraassay and
interassay coefﬁcients of variation (unblinded) were
14.8% and 12.0%, respectively, at 20.2 nmol/L and 3.9%
and 10.8%, respectively, at 72.7 nmol/L. The lowest limit of
detection was 5 nmol/L.
Statistical analyses
Differences between cases and controls regarding age at
blood collection, height, weight, body mass index, and se-
rum concentration of vitamin D were investigated by using
a weighted version of the paired-sample t test (22). Differ-
ences in the categorical baseline characteristics between
cases and controls were compared by using conditional lo-
gistic regression models. To assess the inﬂuence of month of
blood draw on serum concentrations of vitamin D, a simple
mathematical model of log-transformed serum vitamin D
concentration by month of blood collection (as a categorical
variable) was ﬁtted. The ‘‘standardized’’ concentrations of
25(OH)D were calculated by adding the residuals from this
model to the overall mean log serum vitamin D value and
exponentiating thesevalues, and the resulting serum vitamin
D concentrations ‘‘standardized for month of blood collec-
tion’’ were used for all analyses. The standardized concen-
trations were also used to calculate the cutpoints for the
quintiles and the ‘‘low,’’ ‘‘moderate,’’ and ‘‘high’’ categories
of serum 25(OH)D.
Conditional logistic regression models were used to cal-
culate the odds ratios for prostate cancer by quintiles of
25(OH)D concentration, using cutpoints calculated among
controls. Tests for linear trend were obtained by replacing
the quintiles with the logarithm of serum concentration of
25(OH)Dinthemodel.Theeffectsofpotentialconfounders—
body mass index (weight (kg)/height (m)
2 in quartiles),
smoking status (never, former, current), alcohol intake
(<8 g/day, 8–15 g/day, 16–39 g/day,  40 g/day), education
(primary or none, secondary, degree level), marital status
(married and/or cohabiting, not married or cohabiting),
and physical activity (inactive, moderately inactive,
active)—were examined by including these variables in
the logistic regression models. Any missing values were
assigned to a separate category.Likelihood ratio chi-squared
tests were used to examine the heterogeneity of trends in
prostate cancer risk with the logarithm of serum 25(OH)D
concentration between localized (tumor, node, metastasis
staging score of T0 or T1 or T2 and N0 or NX and M0, or
stage coded in the recruitment center as localized; n ¼ 324)
or advanced (T3 or T4 and/or N1þ and/or M1, or stage
coded in the recruitment center as metastatic; n ¼ 122),
low grade (Gleason sum <7 or equivalent (cases coded as
well differentiated or moderately differentiated); n ¼ 361)
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as poorly differentiated or undifferentiated); n ¼ 169), age
at diagnosis (<60 years or  60 years), body mass index
(<25 kg/m
2 or  25 kg/m
2), and country of recruitment.
We also compared the risk of prostate cancer for men with
a diagnosis of prostate cancer less than 4 years (n ¼ 309)
with that for those men diagnosed 4 or more years (n ¼ 343)
after blood collection.
These analyses were repeated by using predeﬁned cut-
points for concentrations of 25(OH)D of <50, 50–<75
and  75 nmol/L to investigate risks associated with low
(<50 nmol/L), moderate (50–<75 nmol/L), and high
( 75 nmol/L) concentrations of vitamin D (20). We also
used the chi-squared test to assess effect modiﬁcation of
al o w( <1,200 mg/day) or high ( 1,200 mg/day) intake of
calcium from food sources on the association between low,
moderate, and high concentrations of serum vitamin D and
risk of prostate cancer.
All statistical analyses were carried out with Stata Statis-
tical Software, release 9 (StataCorp LP, College Station,
Texas). All tests of statistical signiﬁcance were 2-sided,
and P values of <0.05 were considered signiﬁcant.
RESULTS
When characteristics of cases and controls were com-
pared, the groups did not differ appreciably, except that
cases reported slightly less physical activity. The mean con-
centration of 25(OH)D did not differ signiﬁcantly between
cases and controls (P ¼ 0.88) (Table 1).
After we adjusted for age at blood collection, serum con-
centrations of 25(OH)D varied signiﬁcantly by month of
blood collection among the cases and controls (Figure 1),
but there was no signiﬁcant difference in the mean month of
blood collection between the matched sets (P ¼ 0.643).
Mean concentrations were lowest in cases in January (44.7
nmol/L) and in controls in March (42.9 nmol/L), and they
were highest in August (72.4 nmol/L) and September (78.4
nmol/L),respectively.Followingstandardization of25(OH)D
concentrations for month of blood collection and adjustment
forageatbloodcollection,concentrationsvariedsigniﬁcantly
by country of recruitment (P < 0.001) among the controls,
with the highest mean concentrations in men in the United
Kingdom (57.5 nmol/L) and Sweden (56.5 nmol/L) and the
lowest in the Dutch men (45.2 nmol/L) (Figure 2). Following
standardization of 25(OH)D concentrations for month of
blood collection and adjustment for study center, we found
a signiﬁcant inverse association between 25(OH)D concen-
trations and age at blood collection; compared with men
older than age 70 years, men aged 50–54 years had avitamin
D concentration that was 12.5 nmol/L higher (P ¼ 0.001,
results not shown).
The odds ratios for prostate cancer by quintiles of
25(OH)D from conditional logistic regression models con-
ditioned on the matching variables and adjusted for lifestyle
variables are shown in Table 2. Results showed no signiﬁ-
cant association between concentrations of 25(OH)D and
overall risk of prostate cancer, with or without adjustment
for covariates. In the unadjusted results, the risk of prostate
cancer for the highest versus the lowest quintile of serum
concentrations of vitamin D was 1.24 (95% conﬁdence in-
terval: 0.87, 1.79; P for trend ¼ 0.265). After additional
adjustment for body mass index, smoking status, alcohol
intake, education, marital status, and physical activity, the
odds ratio for the highest in comparison to the lowest quin-
tile of vitamin D changed very little (odds ratio ¼ 1.28, 95%
conﬁdence interval: 0.88, 1.88; P for trend ¼ 0.188). There
was no evidence of signiﬁcant heterogeneity in the trends
for the risk of prostate cancer with vitamin D concentration
by stage orgrade or by the age of men at diagnosis (Table 2).
However, when the associations between prostate cancer
risk and 25(OH)D were examined separately by age, a bor-
derline signiﬁcant positive association was observed for
men diagnosed at less than age 60 years (odds ratio for
the highest compared with the lowest quintile ¼ 2.90,
95% conﬁdence interval: 0.85, 9.88; P for trend ¼ 0.046),
and this association was not signiﬁcant for men aged 60
years or older (P for trend ¼ 0.594); however, neither was
the test for heterogeneity between the trends statistically
signiﬁcant (P for heterogeneity ¼ 0.160).
Table 3 results show that the risk of prostate cancer was
not signiﬁcantly different for men with a low (<50 nmol/L)
or a high ( 75 nmol/L) concentration of vitamin D in com-
parison to men with a moderate (50–<75 nmol/L) concen-
tration. There was also no association between these
predeﬁned categories of vitamin D concentrations and risk
of prostate cancer subdivided by stage, grade, or age at di-
agnosis. In addition, we found no association between the
categories of vitamin D and risk of prostate cancer for men
with a high ( 1,200 mg/day) or a low (<1,200 mg/day)
intake of calcium (Table 4).
There was no evidence for signiﬁcant heterogeneity re-
garding the association between serum 25(OH)D and risk of
prostate cancer between men with an early (<4 years) ver-
sus a later ( 4 years) diagnosis (P for heterogeneity ¼
0.857), a high ( 25 kg/m
2) versus a low (<25 kg/m
2) body
mass index (P for heterogeneity ¼ 0.825), or by country
(P for heterogeneity ¼ 0.166, results not shown).
DISCUSSION
The ﬁndings from this large, prospective study show that
the risk of prostate cancer did not vary signiﬁcantly by
serum concentration of 25(OH)D and do not support the
hypothesis that circulating 25(OH)D plays a major role in
the pathogenesis of prostate cancer. Despite the widespread
notion that vitamin D insufﬁciency is an important risk fac-
tor for prostate cancer (17, 18), this theory has not been
substantiated by results from the majority of published pro-
spective studies (5, 7, 8, 10–14). Results from 2 studies have
shown support for lower concentrations of 25(OH)D and
increased risk of prostate cancer. Ahonen et al. (6) demon-
strated a greater risk of prostate cancer for Nordic men with
a 25(OH)D concentration of  40 nmol/L in comparison to
men with concentrations of >40 nmol/L; a second Nordic
study reported a U-shaped relation, with a higher risk for
men with low ( 19 nmol/L) and high ( 80 nmol/L) con-
centrations of 25(OH)D in comparison to men with moder-
ate concentrations (15).
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European Prospective Investigation into Cancer and Nutrition, 1994–2000
Characteristic Cases
(n 5 652)
Controls
(n 5 752)
P
Value
a
No. (%)
b
Smoking
c
Never 217 (34.5) 243 (34.6)
0.82 Former 283 (45.0) 306 (43.6)
Current 129 (20.5) 153 (21.8)
Alcohol consumption
c
<8 g/day 260 (41.5) 321 (45.7)
0.15
8–15 g/day 120 (19.2) 148 (21.1)
16–39 g/day 149 (23.8) 141 (20.1)
 40 g/day 97 (15.5) 92 (13.1)
Physical activity
c
Inactive 103 (17.4) 85 (13.2)
0.04 Moderately inactive 212 (33.8) 218 (33.8)
Active 278 (46.9) 342 (53.0)
Marital status
c
Married and/or cohabiting 480 (88.9) 550 (87.9)
0.59 Not married or cohabiting 60 (11.1) 76 (12.1)
Educational attainment
c
Primary or equivalent 245 (39.8) 290 (41.5)
0.22 Secondary 224 (36.4) 270 (38.6)
Degree 147 (23.9) 139 (19.9)
Mean (SD)
Age at blood collection, years 61.0 (6.3) 60.5 (6.2) 0.15
Weight, kg
c 79.0 (11.1) 80.0 (11.2) 0.10
Height, cm
c 172.3 (6.7) 172.9 (6.9) 0.10
Body mass index, kg/m
2c 26.6 (3.4) 26.8 (3.5) 0.40
Serum 25-hydroxyvitamin D, mean
(95% CI), nmol/L
d 53.6 (52.0, 55.3) 53.5 (51.9, 55.1) 0.88
Year of diagnosis, median (range) 1999 (1994–2005)
Age at diagnosis, mean (SD), years 65.4 (6.1)
Months from blood collection to
diagnosis, median (range)
49 (0–181)
Prostate cancer stage,
e no. (%)
Localized 326 (50.0)
Advanced 122 (18.7)
Unknown 204 (31.3)
Histologic grade,
f no. (%)
Low 362 (55.5)
High 170 (26.1)
Unknown 120 (18.4)
Abbreviations: CI, conﬁdence interval; SD, standard deviation.
a Weightedtestsof meandifference betweencasesandcontrolsineachmatchedset or testsof
association between category and case-control status using conditional logistic regression, as
appropriate.
b Percentages may not add to 100 because of rounding.
c Unknown for some subjects; calculations of percentages exclude missing values.
d Serum concentrations of vitamin D were standardized for month of blood collection.
e Tumor, node, metastasis (TNM) staging score of T0 or T1 or T2 and N0 or NX and M0
(localized); TNM staging score of T3 or T4 and/or N1þ and/or M1 (advanced).
f Gleason sum <7 or equivalent or well or moderately differentiated (low grade); Gleason sum
 7 or poorly differentiated or undifferentiated (high grade).
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regarding an association between vitamin D and risk of
prostate cancer may be due to the variation in vitamin D
concentrations between populations. For instance, the pro-
portion of men with low 25(OH)D concentrations (<50
nmol/L) was higher among the Nordic populations (6, 9,
15) than in most of the US cohorts, where sun exposure is
likely to be greater (5, 11, 13), and/or study populations
were drawn from health-conscious populations (12, 14)
whose intake of vitaminD may be higher.Our data on serum
25(OH)D concentrations suggest a moderate prevalence of
vitamin D insufﬁciency in men across Europe; 39% of the
cases and controls had 25(OH)D concentrations of <50
nmol/L. Our ﬁnding of a null association was also similar
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Figure 1. Geometric mean serum 25-hydroxyvitamin D concentrations, by month of blood draw, in cases and controls in the European Pro-
spective Investigation into Cancer and Nutrition, 1994–2000. Means are geometric means and their corresponding 95% conﬁdence intervals
adjusted for age at blood draw, study center, and their interaction. Solid circles, means for cases; open circles, means for controls. Jan, January;
Feb, February; Mar, March; Apr, April; Jun, June; Jul, July; Aug, August; Sep, September; Oct, October; Nov, November; Dec, December.
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(n = 185)
Greece
(n = 9)
Italy
(n = 61)
Spain
(n = 94)
The Netherlands
(n = 25)
Sweden
(n = 200)
United
Kingdom
(n = 178)
Figure 2. Geometric mean (and 95% conﬁdence interval) serum 25-hydroxyvitamin D concentrations, by country, in controls in the European
Prospective Investigation into Cancer and Nutrition, 1994–2000. Means are geometric means and their corresponding 95% conﬁdence intervals
standardized for month of blood collection and adjusted for age at blood draw.
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ipants had 25(OH)D concentrations of <50 nmol/L (9).
Several studies have evaluated the risk of prostate cancer
associated with concentrations of 1,25(OH)2D, the hor-
monal biologically active form of vitamin D, which has
been shown in experimental studies to reduce the degree
of cell proliferation in the prostate (4, 23, 24). In 2 studies,
the investigators reported a nonsigniﬁcant decreased risk
for men with high concentrations of both vitamin D me-
tabolites (8, 13), whereas several others have reported no
association (7, 10–12, 14). We chose to assess the associ-
ation between prostate cancer risk and serum 25(OH)D and
not 1,25(OH)2D because circulating 25(OH)D (from diet,
supplementation, and sun exposure) is probably a better
marker of an individual’s vitamin D exposure than circu-
lating concentrations of 1,25(OH)2D, which are homeo-
statically controlled, have a half life of 4 hours, and most
probably reﬂect the production of 1,25(OH)2D in the kid-
neys (25). However, a potential limitation of the current
study and all previous epidemiologic studies is that it is not
clear towhat extent circulating25(OH)D reﬂects intrapros-
tatic vitamin D concentrations because 1,25(OH)2Di sp r o -
duced locally in the prostate by cells expressing the
enzyme 25(OH)-1a-hydroxylase (26).
A potential effect modiﬁer of the association between
vitamin D and prostate cancer risk is calcium. A high intake
of calcium coupled with low vitamin D status may increase
the risk of prostate cancer by reducing the amount of
1,25(OH)2D synthesized (27). High levels of calcium may
suppress the release of parathyroid hormone, and the action
of this hormone tightly regulates conversion of 25(OH)D to
1,25(OH)2D in renal cells (28). Nevertheless, these results
showed no evidence that the association between concen-
trations of 25(OH)D and the risk of prostate cancer varied
according to calcium intake, which is consistent with ﬁnd-
ings reported by other studies that have examined the effect
of calcium intake (5, 12, 14) or status (13, 29).
We found no support for a difference in the relation be-
tween vitamin D and prostate cancer by stage or histologic
grade of the disease, which is consistent with others (7, 8,
12–14) apart from Ahn et al. (5), whose results showed
a positive association between 25(OH)D and risk of aggres-
sive disease (Gleason sum  7 or clinical stage III or IV).
These results also showed no heterogeneity in the associa-
tion between 25(OH)D and prostate cancer risk by age at
diagnosis; however, there was a positive association be-
tween serum concentrations of vitamin D and risk of disease
for men diagnosed at less than age 60 years. The majority of
recent studies have reported no substantial difference in the
relation between vitamin D and prostate cancer risk by age
(7, 11–14), with the exception of 2 studies (6, 8). Ahonen
et al. (6) demonstrated an inverse association between
Table 2. Odds Ratios (and 95% Conﬁdence Intervals) for Prostate Cancer by Quintile of 25-Hydroxyvitamin D Concentration in the European
Prospective Investigation into Cancer and Nutrition, 1994–2000
Quintile of 25-Hydroxyvitamin D Concentration
a
Doubling of
Concentration P for
Trend
b
P for
Heterogeneity
c
1
d 23 4 5
OR 95% CI OR 95% CI OR 95% CI OR 95% CI OR 95% CI
Range, nmol/L 2.5 40.4 40.5 50.4 50.5 59.1 59.2 70.8 70.9 163.7
No. of cases 125 143 128 114 142
No. of controls 151 150 151 150 150
Odds ratio
e 1 1.24 0.88, 1.74 1.15 0.82, 1.62 1.01 0.71, 1.45 1.24 0.87, 1.79 1.13 0.91, 1.41 0.265
Adjusted odds ratio
f 1 1.27 0.89, 1.81 1.23 0.85, 1.76 1.06 0.73, 1.55 1.28 0.88, 1.88 1.17 0.93, 1.47 0.188
Prostate cancer stage
f
Localized (n ¼ 326) 1 1.28 0.76, 2.16 1.20 0.72, 1.97 1.09 0.65, 1.83 1.15 0.67, 1.97 1.12 0.80, 1.56 0.508 0.577
Advanced (n ¼ 122) 1 1.61 0.71, 3.65 1.10 0.40, 2.99 0.83 0.32, 2.12 1.13 0.37, 3.43 1.31 0.73, 2.37 0.364
Histologic grade
f
Low (n ¼ 362) 1 1.45 0.89, 2.37 1.37 0.85, 2.21 1.30 0.79, 2.15 1.52 0.91, 2.56 1.29 0.95, 1.74 0.097 0.108
High (n ¼ 170) 1 0.94 0.42, 2.10 0.63 0.26, 1.49 0.86 0.36, 2.05 0.83 0.34, 2.07 0.94 0.52, 1.70 0.846
Age at blood collection
f
<60 years (n ¼ 112) 1 2.02 0.59, 6.90 1.87 0.65, 5.37 3.73 1.06, 13.17 2.90 0.85, 9.88 1.90 0.99, 3.64 0.046 0.160
 60 years (n ¼ 540) 1 1.30 0.89, 1.90 1.19 0.79, 1.77 0.93 0.62, 1.40 1.19 0.78, 1.80 1.07 0.83, 1.39 0.594
Abbreviations: CI, conﬁdence interval; OR, odds ratio.
a Serum concentrations of vitamin D were standardized for month of blood collection.
b Values were obtained with the logarithm of plasma 25-hydroxyvitamin D replacing the categorical plasma 25-hydroxyvitamin D variable in the
model.
c Values relate to likelihood ratio chi-squared tests of heterogeneity between trends for localized and advanced-stage and low- and high-grade
prostate cancer, and for age <60 years and  60 years at blood collection.
d All values of 1 are odds ratios.
e Conditioned on matching variables by using conditional logistic regression.
f Conditioned on matching variables and adjusted for body mass index, smoking, alcohol intake, education, marital status, and physical activity
by using conditional logistic regression.
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Am J Epidemiol 2009;169:1223–1232Table 3. Odds Ratios (and 95% Conﬁdence Intervals) for Prostate Cancer by Predeﬁned
Categories of 25-Hydroxyvitamin D Concentration in the European Prospective Investigation into
Cancer and Nutrition, 1994–2000
Category of 25-Hydroxyvitamin D Concentration
a
P Value
b 1
2
c 3
OR 95% CI OR 95% CI
Range, nmol/L <50 50 74.9  75
No. of cases 258 283 111
No. of controls 286 353 113
Odds ratio
d 1.04 0.82, 1.32 1 1.17 0.85, 1.62 0.265
Adjusted odds ratio
e 1.00 0.78, 1.28 1 1.14 0.82, 1.58 0.188
Prostate cancer stage
e
Localized 1.06 0.75, 1.49 1 1.02 0.64, 1.62 0.508
Advanced 1.22 0.66, 2.25 1 1.17 0.44, 3.13 0.364
Histologic grade
e
Low 0.95 0.69, 1.30 1 1.19 0.76, 1.88 0.097
High 1.25 0.71, 2.19 1 1.29 0.62, 2.70 0.846
Age at blood collection
e
<60 years 1.08 0.74, 1.58 1 1.00 0.62, 1.62 0.046
 60 years 0.83 0.58, 1.19 1 1.33 0.81, 2.18 0.594
Abbreviations: CI, conﬁdence interval; OR, odds ratio.
a Serum concentrations of vitamin D were standardized for month of blood collection.
b Values were obtained with the logarithm of plasma 25-hydroxyvitamin D replacing the cate-
gorical plasma 25-hydroxyvitamin D variable in the model.
c All values of 1 are odds ratios.
d Conditioned on matching variables by using conditional logistic regression.
e Conditioned on matching variables and adjusted for body mass index, smoking, alcohol in-
take, education, marital status, and physical activity by using conditional logistic regression.
Table 4. Odds Ratios (and 95% Conﬁdence Intervals) for Prostate Cancer by Predeﬁned Categories of 25-Hydroxyvitamin D Concentration and
Intake of Dietary Calcium in the European Prospective Investigation into Cancer and Nutrition, 1994–2000
Calcium
Intake,
mg/day
Category of 25-Hydroxyvitamin D Concentration
a (Range, nmol/L)
P
Value
b
1( <50) 2 (50–74.9) 3 (‡75)
No. of
Cases
c
No. of
Controls
c OR 95% CI No. of
Cases
c
No. of
Controls
c OR 95% CI No. of
Cases
c
No. of
Controls
c OR 95% CI
<1,200 196 186 183 216 75 70
 1,200 39 59 63 61 24 24
Unadjusted
d
<1,200 1.19 0.89, 1.60 1 1.25 0.84, 1.86
0.305  1,200 0.73 0.46, 1.16 1.20 0.79, 1.82 1.15 0.63, 2.11
Adjusted
e
<1,200 1.15 0.80, 1.68 1 1.20 0.80, 1.81
0.333  1,200 0.69 0.43, 1.11 1.19 0.78, 1.83 1.09 0.58, 2.05
Abbreviations: CI, conﬁdence interval; OR, odds ratio.
a Serum concentrations of vitamin D were standardized for month of blood collection.
b Values were obtained by using chi-squared tests.
c For 72 cases and 136 controls, information on dietary calcium intake was missing.
d Conditioned on matching variables by using conditional logistic regression.
e Conditioned on matching variables and adjusted for body mass index, smoking, alcohol intake, education, marital status, and physical activity
by using conditional logistic regression.
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aged than age 52 years, and Corder et al. (8) reported a sim-
ilar inverse association but only for men older than age 57
years. Notwithstanding the possibility of a differential effect
by age, both of these subgroup analyses and our own were
based on a small number of cases (n ¼ 67, n ¼ 91, and n ¼
112 men, respectively), and, because a number of compar-
isons were made in our analyses, the role of chance cannot
be excluded.
Others have also demonstrated that the inﬂuence of low
concentrations of 25(OH)D on the risk of prostate cancer
differed according to several polymorphisms located on
the vitamin D receptor gene, including Cdx2, Fok1,a n d
Bsm1 (12, 30). Moreover, evidence also suggests that poly-
morphisms in the vitamin D binding protein affect circu-
lating concentrations of 25(OH)D (31). Given that the
genotype of vitamin D receptor or vitamin D binding pro-
tein was not determined for the men in this study, our
results do not rule out the possibility that low levels of
circulating 25(OH)D may be associated with a greater risk
of prostate cancer for certain individuals with a speciﬁc
genotype or haplotype.
Strengths of this study include the large number of cases,
prospective design, and inclusion of men from a number of
European countries. One of the limitations is that partici-
pants were not matched on month of blood collection. Be-
cause serum 25(OH)D concentrations varied according to
the month in which the blood sample was collected, vitamin
D values were standardized for month of blood collection
before we assessed the association between vitamin D and
risk of prostate cancer so as to minimize the risk of con-
founding by season of blood collection. The mean preclin-
ical duration of prostate cancer has been estimated to be
10 years (32); in this study, the median time between blood
collection and diagnosis of cases was 4 years. Thus, a poten-
tial limitation of this analysis was that serum 25(OH)D con-
centrations in the cases reﬂected vitamin D status at a time
when early preclinical tumors were present rather than prior
to initiation of tumor growth. It is possible that any sub-
clinical tumors present at the time of blood collection inﬂu-
enced serum concentrations of 25(OH)D. Notwithstanding
these limitations, exclusion of cases diagnosed in the ﬁrst
4 years of follow-up did not alter the main ﬁndings.
In conclusion, the ﬁndings from this large prospective
study of European men showed no strong association be-
tween serum concentrations of 25(OH)D and risk of total
prostate cancer. Taken together with the results from other
prospectivestudies,thetotalityofevidenceindicatesthatlow
vitaminDconcentrationsdonothaveanimportantroleinthe
etiology of prostate cancer. Further pooled analyses would
help to determine whether there are any subgroup associa-
tions or an effect of the exposure distribution and range of
vitamin D concentrations on the risk of prostate cancer.
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